Filing Details

Accession Number:
0001209191-19-025789
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-04-24 18:04:19
Reporting Period:
2019-04-22
Accepted Time:
2019-04-24 18:04:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595893 Turning Point Therapeutics Inc. TPTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1595117 Simeon George C/o S.r.one, Limited
161 Washington Street, Suite 500
Conshohocken PA 19428
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-04-22 1,120,730 $0.00 1,120,730 No 4 C Indirect By S.R.One, Limited
Common Stock Acquisiton 2019-04-22 546,820 $0.00 1,667,550 No 4 C Indirect By S.R.One, Limited
Common Stock Acquisiton 2019-04-22 325,000 $18.00 1,992,550 No 4 P Indirect By S.R.One, Limited
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By S.R.One, Limited
No 4 C Indirect By S.R.One, Limited
No 4 P Indirect By S.R.One, Limited
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2019-04-22 15,000 $0.00 15,000 $27.06
Common Stock Series C Preferred Stock Disposition 2019-04-22 4,314,809 $0.00 1,120,730 $0.00
Common Stock Series D Preferred Stock Disposition 2019-04-22 2,105,259 $0.00 546,820 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,000 2029-04-21 No 4 A Direct
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date.
  2. S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein. Simeon J. George holds the title of Vice President at S.R. One, Limited and is an employee of GlaxoSmithKline LLC, a wholly-owned subsidiary of GlaxoSmithKline plc. Mr. George disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.
  3. The shares were purchased at the Issuer's initial public offering.
  4. The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders.
  5. As a Vice President of S.R. One, Limited and an employee of GlaxoSmithKline LLC, Simeon George is obligated to transfer any shares issued under the stock option to S.R One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.